Cipla Limited
23 Jul 2026
-
My first question is on EBITDA margin. Since we are retaining the EBITDA margin for guidance of around 20%, so just wanted to and which is subject to these new launches. So I just wanted to understand, hypothetically, if we get delayed by for these launche s, so what can be the EBITDA margin without Lanreotide and the new launches?
Read in transcript -
Yes. But is there a threshold level beyond which we cannot grow? So, if you can just guide us on the threshold level that we can look at?
Read in transcript -
Sure. And my second question is on the domestic side. So now our chronic portfolio has reached 60%. So again, with the growth in Yurpeak and how do we see scaling up of chronic segment? Again, is there a level that we can quantify in next 2, 3 years time?
Read in transcript